KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Operating Expenses (2018 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Other Operating Expenses for 6 consecutive years, with $263.4 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 191.51% to $263.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$26.8 million through Dec 2025, up 93.79% year-over-year, with the annual reading at -$26.8 million for FY2025, 91.16% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $263.4 million at Xenon Pharmaceuticals, up from -$102.3 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $263.4 million in Q4 2025, with the low at -$287.9 million in Q4 2024.
  • Average Other Operating Expenses over 4 years is -$81.0 million, with a median of -$93.8 million recorded in 2025.
  • Peak annual rise in Other Operating Expenses hit 191.51% in 2025, while the deepest fall reached 2144.57% in 2025.
  • Over 4 years, Other Operating Expenses stood at -$133.6 million in 2022, then crashed by 63.2% to -$218.1 million in 2023, then crashed by 31.99% to -$287.9 million in 2024, then soared by 191.51% to $263.4 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $263.4 million, -$102.3 million, and -$102.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.